Why are investors not interested in my radiotracer? The industrial and regulatory constraints in the development of radiopharmaceuticals

Nuclear Medicine and Biology

Volumn 40, Issue 2, 2013, Pages 155-166

  Zimmermann, Richard G ^a  

^a Chrysalium Consulting SARL   (France)

Author keywords

Economics; Investment; Radionuclide selection; Radiopharmaceutical development

Indexed keywords

FLORBETABEN; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; FLUTEMETAMOL F 18; GALLIUM 67; GIRENTUXIMAB I 124; IBRITUMOMAB TIUXETAN; INDIUM 111; IODINE 123; IODINE 124; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; RADIUM CHLORIDE RA 223; TECHNETIUM 99M; TETROFOSMIN TC 99M;

ALZHEIMER DISEASE; BIOREACTOR; CLINICAL TRIAL (TOPIC); COMPETITION; CYCLOTRON; DRUG APPROVAL; DRUG CONTROL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; DRUG SYNTHESIS; FEASIBILITY STUDY; GENERATOR; GOOD CLINICAL PRACTICE; GOOD MANUFACTURING PRACTICE; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE NEED; HUMAN; IMAGE QUALITY; INVESTMENT; ISOTOPE LABELING; NONHUMAN; NUCLEAR MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; RADIOCHEMISTRY; REIMBURSEMENT; REVIEW; RISK BENEFIT ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; INVESTMENTS; RADIOACTIVE TRACERS; RADIOPHARMACEUTICALS; SOCIAL CONTROL, FORMAL;

EID: 84872930341     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.10.012     Document Type: Review

References (34)

1. Zimmermann R.G. Développement de radiopharmaceutiques et contraintes industrielles (Development of radiopharmaceuticals and industrial constraints). Médecine Nucléaire - Imagerie Fonctionnelle et Métabolique 2005, 29(4):157-161.
2. Zimmermann R.G. Industrial constraints in the selection of radionuclides and the development of new radiopharmaceuticals. World J Nucl Med 2008, 7:126-134.
3. Freudenberg L.S., Beyer T. Subjective perception of radiation risk. J Nucl Med 2011, 52:29S-35S.
4. Schelbert H.R. Nuclear medicine at a crossroad. J Nucl Med 2011, 52:10S-15S.
5. Zimmermann R.G. Research Strategy - Commentary: the promise of nuclear medicine. Med Nous 2009, 3(10):20.
6. Molecular Imaging and Contrast Agent Database (MICAD) and the Molecular Imaging Probes and Contrast Agents List; MICAD: (15.09.2012) and for the MiCAList: (15.09.2012). http://www.ncbi.nlm.nih.gov/books/NBK5330.
7. Zimmermann R.G. The Oncidium Foundation: a perspective. World J Nucl Med 2011, 10(2):157. O-030 - Abstracts for the 4th International Conference on Radiopharmaceutical Therapy (ICRT-2011), Ho Chi Minh City, 28 November - 2 December 2011; www.oncidium-life.org (15.09.2012).
8. Zimmermann R. Nuclear medicine: radioactivity in diagnosis and therapy 2007, 176. EDP Sciences, Les Ulis, France, work for the use of general public.
9. Technetium-99m radiopharmaceuticals: status and trends, IAEA Radioisotopes and Radiopharmaceuticals Series No. 1 (2009); full text available under (28.08.2012). http://www-pub.iaea.org/MTCD/publications/PDF/Pub1405_web.pdf.
10. Pasqualini R. Present-day development of Tc-99m radiopharmaceuticals: an economical challenge for pharmaceutical companies. The IBA involvement, chapter from: Eckelman W., Review of new clinical applications of radiometal labeled radiopharmaceuticals. Nucl Med Biol 2011, 38:613-616.
11. 99mTc shortage.
12. Bourguignon M.H., Pauwels E.K.J., Loc'het C., Mazière B. Iodine-123 labeled radiopharmaceuticals and single-photon emission tomography: a natural liaison. Eur J Nucl Med Mol Imaging 1997, 24:331-344.
13. Clinical trials database High dose Indium-111 pentetreotide therapy in somatostatin receptor expressing neuroendocrine neoplasms 15.09.2012. http://clinicaltrials.gov/ct2/show/NCT00442533.
14. Schwaiger M., Wester H.J. How many PET tracers do we need?. J Nucl Med 2011, 52:36S-41S.
15. Koehler L., Gagnon K., McQuarrie S., Wuest F. Iodine-124: a promising positron emitter for organic PET chemistry. Molecules 2010, 15:2686-2718.
16. Chacko A.M., Divgi C.R. Radiopharmaceutical chemistry with iodine-124: a non-standard radiohalogen for positron emission tomography. Med Chem 2011, 7(5):395-412.
17. Verel I., Visser G.W., Boerman O.C., van Eerd J.E., Finn R., Boellaard R., et al. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiopharm 2003, 18(4):655-661.
18. 188Re Generators (2009); full text under 28.08.2012. http://www-pub.iaea.org/MTCD/publications/PDF/trs470_web.pdf.
19. IAEA Technical report series TRS 468 Cyclotron produced radionuclides: physical characteristics and production methods (2009); full text under 28.08.2012. http://www-pub.iaea.org/MTCD/publications/PDF/trs468_web.pdf.
20. Qaim S.M. Development of novel positron emitters for medical applications: nuclear and radiochemical aspects. Radiochim Acta 2011, 99:611-625.
21. Qaim S.M. Decay data and production yields of some non-standard positron emitters used in PET. Q J Nucl Med Mol Imaging 2008, 52(2):111-120.
22. Al-Nahhas A., Win Z., Szyszko T., Singh A., Nanni C., Fanti S., Rubello D. Gallium-68 PET: a new frontier in receptor cancer imaging. Anticancer Res 2007, 27(6B):4087-4094.
23. IAEA Technical reports series TRS 458 Comparative evaluation of therapeutic radiopharmaceuticals (2007); full text available under 28.08.2012. http://www-pub.iaea.org/MTCD/publications/PDF/trs458_web.pdf.
24. Ketring A.R., Ehrhardt G.J., Embree M.F., Bailey K.D., Tyler T.T., Gawenis J.A., Jurisson S.S., Engelbrecht H.P., Smith C.J., Cutler C.S. Production and supply of high specific activity radioisotopes for radiotherapy applications. ALASBIMN J 2003, Article N° AJ19-2.
25. Dadachova E. Cancer therapy with alpha-emitters labeled peptides. Semin Nucl Med 2010, 40(3):204-208.
26. Cheetham PJ, Petrylak DP, Alpha particles as radiopharmaceuticals in the treatment of bone metastases: mechanism of action of radium-223 chloride (Alpharadin) and radiation protection. Oncology (Williston Park), 2012;26(4):330-7, 341.
27. IAEA Live Chart of Radionuclides 2.5 Table of nuclides 28.08.2012. http://www-nds.iaea.org/relnsd/vchart.
28. IAEA Reports on Radionuclides Technical Report Series TRS 26.08.2012. http://srsweb.org/IAEAPubs.html.
29. Van Velzen A.J.M., Chemaly C.R. A survey on radioisotope production capabilities, Therapeutic radioisotope usage in Europe - Expected trends in terms of research activities; October 2005, EUR 21874 EN 15.06.2012. http://ie.jrc.ec.europa.eu/publications/scientific_publications/2005/EUR21874EN.pdf.
30. Barbet J., Chatal J.F., Gauché F., Martino J. Which radionuclides will nuclear oncology need tomorrow?. Eur J Nucl Med Mol Imaging 2006, 33:627-630.
31. DiMasi J., Hansen R.W., Grabowski H.G. The price of innovation: new estimates of drug development costs; J. Health Econ 2003, 22(2):151-185.
32. Nunn A.D. The cost of developing imaging agents for routine clinical use. Invest Radiol 2006, 41(3):206-212.
33. Nunn A.D. The cost of bringing a radiopharmaceutical to the patient's bedside. J Nucl Med 2007, 48:169.
34. Light D., Warburton R. Demythologizing the high costs of pharmaceutical research. BioSocieties 2011, 1:1-17. 15.09.2012. http://www.pharmamyths.net/files/Biosocieties_2011_Myths_of_High_Drug_Research_Costs.pdf.